Senolytics and senostatics as adjuvant tumour therapy

Cell senescence is a driver of ageing, frailty, age-associated disease and functional decline. In oncology, tumour cell senescence may contribute to the effect of adjuvant therapies, as it blocks tumour growth. However, this is frequently incomplete, and tumour cells that recover from senescence may...

Descripción completa

Detalles Bibliográficos
Autores principales: Short, Susan, Fielder, Edward, Miwa, Satomi, von Zglinicki, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441870/
https://www.ncbi.nlm.nih.gov/pubmed/30737084
http://dx.doi.org/10.1016/j.ebiom.2019.01.056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441870/
https://www.ncbi.nlm.nih.gov/pubmed/30737084
http://dx.doi.org/10.1016/j.ebiom.2019.01.056

Ejemplares similares